Drug intelligence / Profile preview

SDGR5

Development stage: Unknown
Lead developer: Schrödinger
Modality: Small Molecules

Overview

SDGR5 is a small molecule inhibitor of the SOS1/KRAS protein-protein interaction developed by Schrödinger in collaboration with Bristol Myers Squibb, targeting the RAS signaling pathway to block oncogenic KRAS activation. It is designed to disrupt the interaction between Son of Sevenless 1 (SOS1) guanine nucleotide exchange factor and KRAS, preventing GDP-to-GTP exchange that drives tumor growth in cancers with KRAS mutations. Limited public data is available on its clinical status or specific indications, positioning it as an early-stage investigational asset in oncology.[11][13]

Other names: SDGR5 program - SchrodingerSDGR-5 program - SchrodingerSDGR 5 program - SchrodingerSDGR5-SOS1 / KRAS

Targets

MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1)

Beyond the preview

Go deeper on SDGR5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDGR5.

Explore the full profile